Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PYO2
- Development stage
- Preclinical
- Lead developer
- San Diego State University
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Intravenous
01
Overview
PYO2 is a lytic bacteriophage (specifically a myovirus belonging to the genus *Litunavirus*) that targets *Pseudomonas aeruginosa*. It specifically binds to the O-antigen of the lipopolysaccharide (LPS) on the outer membrane of *P. aeruginosa* to infect and lyse the bacterial cells. PYO2 is being investigated, particularly in combination with last-line antibiotics such as beta-lactams (e.g., aztreonam/avibactam) and polymyxin B, for the treatment of extensively drug-resistant (XDR) *P. aeruginosa* infections. Research has shown that resistance development to PYO2 selects for a bacterial subpopulation with increased outer membrane permeability, thereby restoring or enhancing sensitivity to beta-lactam antibiotics (collateral sensitivity).
- Other names
- Pseudomonas phage PYO2phage PYO2
Beyond the preview
Go deeper on PYO2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PYO2.